Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BEZ235+ MEK162 · 1 trial · 2 indications
A complete treatment cycle is defined as 28 days of daily continuois treatment with study drug combination
| Arm | Type | Description |
|---|---|---|
| BEZ235 + MEK162 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BEZ235 + MEK162 | DRUG | - |
Inclusion Criteria: * histologically/cytologically confirmed, advanced non resectable solid tumors * Measurable or non-measurable, but evaluable disease as determined by RECIST 1.0 Exclusion Criteria: * Patients with primary CNS tumor or CNS tumor involvement * Diabetes mellitus - Unacceptable oc...
BEZ235+ MEK162 is an investigational combination of two small molecule drugs studied together in oncology. It was evaluated in adults with advanced solid tumors. The combination was tested in a single Phase 1 clinical trial and is not an approved therapy.
BEZ235+ MEK162 was studied for the treatment of unspecified adult solid tumors. The research involved patients with advanced solid tumors, and the trial protocol did not restrict enrollment to a specific tumor type. It is an investigational combination and has not been approved for any indication.
Pfizer, Inc. is the developer of BEZ235+ MEK162. The company, which trades under the ticker PFE, sponsored the clinical research of this drug combination. Pfizer is a global pharmaceutical company.
BEZ235+ MEK162 is in Phase 1 clinical development. It has completed one Phase 1 trial and is not currently active in any trials. The combination remains investigational and has not received FDA approval.
BEZ235+ MEK162 was evaluated in a single Phase 1 clinical trial, NCT01337765, titled "Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients." The trial is completed and enrolled 29 participants across the United States, Australia, Canada, France, and Spain.